Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.71 USD | +0.27% | +5.61% | -9.90% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.90% | 3.4B | D | ||
-4.66% | 86.13B | A- | ||
+1.32% | 39.82B | A- | ||
-19.27% | 30.42B | B- | ||
+57.86% | 25.23B | A | ||
-16.09% | 15.35B | C | ||
-9.14% | 11.95B | D+ | ||
-17.69% | 11.6B | B- | ||
-43.00% | 11.51B | B | ||
+5.24% | 8.71B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AXSM Stock
- Ratings Axsome Therapeutics, Inc.